<?xml version="1.0" encoding="UTF-8"?>
<p id="p0185">As previously mentioned, SARS-CoV-2 also uses the ACE-2 receptor for its attachment and TMPRSS2 for S-protein priming 
 <xref rid="b0165" ref-type="bibr">[33]</xref>. Camostat, a serine protease inhibitor that has been approved in Japan for the treatment of pancreatitis, was shown to block the cellular entry of SARS-CoV-2 by inhibiting TMPRSS2 
 <xref rid="b0165" ref-type="bibr">[33]</xref>. Having already established its safety profile, camostat might prove to be a valuable drug in the arsenal, which can be repurposed to combat COVID-19. Camostat is currently under clinical trials (NCT04338906, NCT04321096) to prove its efficacy for the treatment of COVID-19.
</p>
